Sign In
Buy LIVN
$80.14
-0.91 (-1.12%)
At Close: Jul 31, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
08:15pm, Monday, 17'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to cont
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
09:00am, Thursday, 06'th Jun 2024
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced preliminary results for the unipolar cohort of the RECOVER study, assessing use of VNS Therapy in treatment-resistant depression.
LivaNova to Present at the Goldman Sachs Healthcare Conference
09:00am, Thursday, 23'rd May 2024
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present a fireside chat at the Goldman Sachs Conference in Miami, Florida at 1:20 pm ET on June
LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates
08:10am, Wednesday, 01'st May 2024
LivaNova (LIVN) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago.
LivaNova Reports First-Quarter 2024 Results
06:00am, Wednesday, 01'st May 2024
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
09:00am, Tuesday, 30'th Apr 2024
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer, effective May 13, 2024.
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
04:03pm, Thursday, 25'th Apr 2024
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova's wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident in late 2023.
LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 24'th Apr 2024
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova to Announce First-Quarter 2024 Results
09:00am, Thursday, 21'st Mar 2024
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova will host a conference call to discuss its first-quarter 2024 results on Wed, May 1, 2024 at 1 p.m. London time (8 a.m. ET).
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
05:51am, Thursday, 21'st Mar 2024
LivaNova (LIVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its OSPREY clinical study has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
09:55pm, Tuesday, 05'th Mar 2024
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 issued in a private offering.
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
04:44pm, Monday, 04'th Mar 2024
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 in a private offering.
LivaNova to Present at the Barclays Global Healthcare Conference
09:00am, Monday, 04'th Mar 2024
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present in a fireside chat at the Barclays Conference in Miami, Florida at 10:45 am ET on March
LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates
08:11am, Wednesday, 21'st Feb 2024
LivaNova (LIVN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.81 per share a year ago.
